New blood test could personalise depression treatmentBMJ 2016; 353 doi: https://doi.org/10.1136/bmj.i3203 (Published 08 June 2016) Cite this as: BMJ 2016;353:i3203
- Jacqui Wise
Scientists have developed a blood test to predict whether depressed patients will respond to common antidepressants. They said that this could herald a new area of personalised treatment for people with depression, where patients who have blood inflammation above a certain threshold could receive more aggressive treatment.
The research, published in the International Journal of Neuropsychopharmacology,1 focused on two biomarkers that measure blood inflammation: macrophage migration inhibitory factor and interleukin 1β. Previous research has shown that patients with depression who are resistant to conventional antidepressants have higher concentrations of …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial